In stroke patients, MBP immunoreactivity in the CLNs correlated with larger infarct volumes and poor clinical outcomes, while MAP2 immunoreactivity correlated with smaller stroke volumes and better functional recovery (Planas et al. 2012). The gene discussed is MAP2; the disease is Stroke.